ClinicalTrials.gg
CompletedNCT02343250IDCVUpdated Jan 13, 2016

A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan

A Phase 1 interventional study of Cilnidipine/Valsartan and Cilnidipine+Valsartan in Hypertension, sponsored by IlDong Pharmaceutical Co Ltd. Completed. Open to male participants aged 19 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-01-13.

Sponsored by IlDong Pharmaceutical Co Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
19 Years to 40 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
114th of 139
54 · median 198
Started
2015
the only one that year
Phase 1
10 of 140
none open now
Registered
126th of 140
by date
Lead sponsor
2 of 140
IlDong Pharmaceutical Co Ltd

Among the 140 studies testing valsartan in Hypertension, this one is the 114th largest by enrollment of the 139 interventional ones that give a count, is the only one that started in 2015, is one of 10 in phase 1, and was the 126th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 19 Years to 40 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Volunteers

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
19 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 20 and 40
  • Signed

Exclusion criteria

Exclusion Criteria:

  • Has a history of to IP ingredients
  • Hypertension of hypotension
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Cinidipine/Valsartan tablet

    Cinidipine/Valsartan tablet

    Drug: Cilnidipine/Valsartan · Drug: Cilnidipine+Valsartan

  • Active comparator
    Cilnidipine+Valsartan

    coadministration of cilinidipine and valsartan

    Drug: Cilnidipine+Valsartan · Drug: Cilnidipine/Valsartan

Interventions

  • DrugCilnidipine/Valsartan

    Drug pages: Cilnidipine · Valsartan

    Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle

  • DrugCilnidipine+Valsartan

    Drug pages: Cilnidipine · Valsartan

    Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle

  • DrugCilnidipine/Valsartan

    Drug pages: Cilnidipine · Valsartan

    Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle

  • DrugCilnidipine+Valsartan

    Drug pages: Cilnidipine · Valsartan

    Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle

06

What researchers measure

Primary outcomes

  1. AUClast

    Time frame: 0~24hr

  2. Cmax

    Time frame: 0~24hr

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015 and a primary completion of Mar 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2015
First posted
Jan 21, 2015
Start
Mar 2015
Primary completionActual
Mar 2015
Last update
Jan 13, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02343250
Responsible party
Sponsor
First posted
Jan 21, 2015
Start date
Mar 2015
Primary completion
Mar 2015
Last update
Jan 13, 2016

Study contacts

Kyungsang Yu, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cilnidipine · Valsartan

Start the discussion